These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 552592)

  • 21. Diuretic effect and duration of action of a single intravenous dose of furosemide in uremia and myocardial infarction.
    Farghali H; Al Zuhair H; Al Windawi S; Al Hamdi A; Fariduddin M
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):659-64. PubMed ID: 6526541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit.
    Pichette V; Geadah D; du Souich P
    Drug Metab Dispos; 1999 Jan; 27(1):81-5. PubMed ID: 9884313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hepatic clearance of drugs. Physiological and pharmacokinetic considerations].
    Pellegrin P; Lesne M
    J Pharmacol; 1983; 14(2):107-39. PubMed ID: 6865443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
    Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog.
    Cohen MR; Hinsch E; Vergona R; Ryan J; Kolis SJ; Schwartz MA
    J Pharmacol Exp Ther; 1976 Jun; 197(3):697-702. PubMed ID: 932999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
    González G; Arancibia A; Rivas MI; Caro P; Antezana C
    Eur J Clin Pharmacol; 1982; 22(4):315-20. PubMed ID: 7106167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
    Fuller R; Hoppel C; Ingalls ST
    Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model.
    Zou YH; Liu X; Khlentzos AM; Asadian P; Li P; Thorling CA; Robertson TA; Fletcher LM; Crawford DH; Roberts MS
    Drug Metab Pharmacokinet; 2010; 25(5):442-9. PubMed ID: 20877138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.
    Naranjo CA; Busto U; Janecek E; Ruiz I; Roach CA; Kaplan K
    Br J Clin Pharmacol; 1983 Apr; 15(4):451-8. PubMed ID: 6849781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients.
    Uchino K; Isozaki S; Amano J; Tanaka N; Saitoh Y; Nakagawa F; Tamura Z; Oka H
    J Pharmacobiodyn; 1983 Sep; 6(9):684-91. PubMed ID: 6655548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of drugs in mutant Nagase analbuminemic rats and responses to select diuretics.
    Lee JH; Lee YJ; Oh E
    J Pharm Pharmacol; 2014 Jan; 66(1):2-13. PubMed ID: 24151919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terminal half-lives of drugs studied in patients with hepatic diseases.
    Closson RG
    Am J Hosp Pharm; 1977 May; 34(5):520-4. PubMed ID: 326043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic disease and drug pharmacokinetics.
    Williams RL; Mamelok RD
    Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dangerous drugs in hepatic insufficiency].
    Isal JP; Caulin C
    Med Chir Dig; 1979; 8(5):447-9. PubMed ID: 534025
    [No Abstract]   [Full Text] [Related]  

  • 39. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
    Ogata H; Kawatsu Y; Maruyama Y; Machida K; Haga T
    Eur J Clin Pharmacol; 1985; 28(1):53-9. PubMed ID: 3987786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics in liver disease.
    Breimer DD
    Pharm Weekbl Sci; 1987 Apr; 9(2):79-84. PubMed ID: 3295764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.